Results 241 to 250 of about 24,541,782 (296)
Retraction for Murmu et al., Dynamic antagonism between RNA-binding protein CUGBP2 and cyclooxygenase-2-mediated prostaglandin E<sub>2</sub> in radiation damage. [PDF]
Proc Natl Acad Sci U S Aeuropepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Cyclooxygenase-2 in oncogenesis
Clinica Chimica Acta, 2011Compelling experimental and clinical evidence supports the notion that cyclooxygenase-2, the inducible isoform of cyclooxygenase, plays a crucial role in oncogenesis. Clinical and epidemiological data indicate that aberrant regulation of cyclooxygenase-2 in certain solid tumors and hematological malignancies is associated with adverse clinical outcome.
Maria Teresa Rizzo
exaly +3 more sources
Cyclooxygenase-2 and carcinogenesis
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2000Numerous investigations have shown that COX-2 is a participant in the pathway of colon carcinogenesis, especially when mutation of the APC tumor suppressor is the initiating event. Moreover, it seems that the amount of COX-2 is important, since there is a correlation between its level of expression and the size of the tumors and their propensity to ...
S M, Prescott, F A, Fitzpatrick
openaire +2 more sources
Cyclooxygenase-2 and atherosclerosis
Current Opinion in Lipidology, 2002Cyclooxygenase regulates the production of eicosanoids, which modulate physiologic processes in the vessel wall contributing to atherosclerosis and thrombosis, including platelet aggregation, control of vascular tone, and the local inflammatory response.
MacRae F, Linton, Sergio, Fazio
openaire +2 more sources
Cyclooxygenase 2 and the kidney
Current Opinion in Nephrology and Hypertension, 2001Cyclooxygenase metabolizes arachidonic acid to a family of bioactive fatty acids designated prostaglandins. Two isoforms of cyclooxygenase exist, designated COX1 and COX2. These isoforms are expressed in distinct but important areas of the kidney. COX1 predominates in vascular smooth muscle and collecting ducts, whereas COX2 predominates in the macula ...
M D, Breyer, R C, Harris
openaire +2 more sources
Current Opinion in Internal Medicine, 2006
The purpose of this review is to summarize new information regarding the use of selective inhibitors of the cyclooxygenase-2 enzyme, emphasizing recent developments regarding cardiovascular risk.Selective cyclooxygenase-2 inhibitors are as effective as nonselective nonsteroidal antiinflammatory drugs in relieving pain and inflammation but are ...
Christopher J, Hawkey, Paul J, Fortun
openaire +2 more sources
The purpose of this review is to summarize new information regarding the use of selective inhibitors of the cyclooxygenase-2 enzyme, emphasizing recent developments regarding cardiovascular risk.Selective cyclooxygenase-2 inhibitors are as effective as nonselective nonsteroidal antiinflammatory drugs in relieving pain and inflammation but are ...
Christopher J, Hawkey, Paul J, Fortun
openaire +2 more sources
Cyclooxygenase-2 Inhibition and Coagulation
Journal of Cardiovascular Pharmacology, 2006Selective inhibitors of cyclooxygenase-2 (COX-2) have come under scrutiny because of a possibly increased thrombotic risk observed in retrospective studies and comparatively small cancer trials. Indeed, inhibition of COX-2 may favor a prothrombotic environment by suppressing endothelial prostacyclin synthesis while leaving COX-1-dependent platelet ...
Steffel, J +3 more
openaire +4 more sources
2001
Publisher Summary This chapter deals with aspects of the discovery and development of Cyclooxygenase-2 (Cox-2) inhibitors, which, in the case of rofecoxib, resulted from efforts that were initiated in July of 1992 and culminated in the launch of the drug in the United States in June of 1999. Nonsteroidal antiinflammatory drugs (NSAIDs) have long been
A S, Nies, M J, Gresser
openaire +2 more sources
Publisher Summary This chapter deals with aspects of the discovery and development of Cyclooxygenase-2 (Cox-2) inhibitors, which, in the case of rofecoxib, resulted from efforts that were initiated in July of 1992 and culminated in the launch of the drug in the United States in June of 1999. Nonsteroidal antiinflammatory drugs (NSAIDs) have long been
A S, Nies, M J, Gresser
openaire +2 more sources
Current Pharmaceutical Design, 2003
In mammalian cells, eicosanoid biosynthesis is usually initiated by the activation of phospholipase A(2) and the release of arachidonic acid from membrane phospholipids in response to the interaction of a stimulus with a receptor on the cell surface. Arachidonic acid is subsequently transformed by the enzyme cyclooxygenase (COX) to prostaglandins (PGs)
openaire +2 more sources
In mammalian cells, eicosanoid biosynthesis is usually initiated by the activation of phospholipase A(2) and the release of arachidonic acid from membrane phospholipids in response to the interaction of a stimulus with a receptor on the cell surface. Arachidonic acid is subsequently transformed by the enzyme cyclooxygenase (COX) to prostaglandins (PGs)
openaire +2 more sources
Cyclooxygenase-2 and inflammation in atherosclerosis
Current Opinion in Pharmacology, 2004By regulating the production of eicosanoids, cyclooxygenase (COX) modulates processes contributing to atherosclerosis and thrombosis, including platelet aggregation and the local inflammatory response. COX-2, a key mediator of inflammation, is upregulated in activated monocyte/macrophages, suggesting that COX-2 inhibition might reduce atherogenesis ...
MacRae F, Linton, Sergio, Fazio
openaire +2 more sources